Tarsus Pharmaceuticals, Inc. Common Stock (TARS) is a publicly traded Healthcare sector company. As of May 21, 2026, TARS trades at $64.79 with a market cap of $2.70B and a P/E ratio of -56.22. TARS moved +5.71% today. Year to date, TARS is -18.76%; over the trailing twelve months it is +44.36%. Its 52-week range spans $31.36 to $85.25. Analyst consensus is strong buy with an average price target of $95.17. Rallies surfaces TARS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
TARS financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. TARS recently traded at $64.79. Market cap is $2.70B. P/E ratio is -56.22. Revenue is $535.08M.
| Metric | Value |
|---|---|
| Price | $64.79 |
| Market Cap | $2.70B |
| P/E Ratio | -56.22 |
| EPS | $-1.13 |
| Dividend Yield | 0.00% |
| 52-Week High | $85.25 |
| 52-Week Low | $31.36 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $535.08M |
| Net Income | $-48.27M |
| Gross Margin | 0.00% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $451.36M | $-66.42M | $-1.59 |
| 2024 | $182.95M | $-115.55M | $-3.07 |
| 2023 | $17.45M | $-135.89M | $-4.62 |
| 2022 | $25.82M | $-62.09M | $-2.52 |
8 analysts cover TARS: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $95.17.